Marshall Wace’s Intra-Cellular Therapies Inc. ITCI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-440,668
| Closed | -$58.1M | – | 3318 |
|
|
2025
Q1 | $58.1M | Sell |
440,668
-639,089
| -59% | -$79.6M | 0.07% | 243 |
|
|
2024
Q4 | $90.2M | Sell |
1,079,757
-81,216
| -7% | -$6.67M | 0.11% | 171 |
|
|
2024
Q3 | $84.9M | Buy |
1,160,973
+661,958
| +133% | +$49.8M | 0.1% | 172 |
|
|
2024
Q2 | $34.2M | Buy |
+499,015
| New | +$34.6M | 0.05% | 338 |
|
|
2024
Q1 | – | Sell |
-24,249
| Closed | -$1.74M | – | 2878 |
|
|
2023
Q4 | $1.74M | Sell |
24,249
-18,699
| -44% | -$1.08M | ﹤0.01% | 1279 |
|
|
2023
Q3 | $2.24M | Sell |
42,948
-65,500
| -60% | -$3.82M | ﹤0.01% | 1174 |
|
|
2023
Q2 | $6.87M | Buy |
+108,448
| New | +$6.76M | 0.01% | 892 |
|
|
2022
Q2 | – | Sell |
-2,519,764
| Closed | -$154M | – | 3943 |
|
|
2022
Q1 | $154M | Buy |
2,519,764
+131,470
| +6% | +$6.83M | 0.29% | 59 |
|
|
2021
Q4 | $125M | Buy |
2,388,294
+92,660
| +4% | +$3.89M | 0.23% | 82 |
|
|
2021
Q3 | $85.6M | Sell |
2,295,634
-475,670
| -17% | -$16.5M | 0.36% | 35 |
|
|
2021
Q2 | $113M | Sell |
2,771,304
-63,156
| -2% | -$2.33M | 0.51% | 23 |
|
|
2021
Q1 | $96.2M | Sell |
2,834,460
-181,272
| -6% | -$6.29M | 0.44% | 33 |
|
|
2020
Q4 | $95.9M | Buy |
3,015,732
+3,355
| +0.1% | +$88.2K | 0.52% | 34 |
|
|
2020
Q3 | $77.3M | Buy |
3,012,377
+1,694,447
| +129% | +$38.7M | 0.49% | 38 |
|
|
2020
Q2 | $33.8M | Buy |
1,317,930
+633,152
| +92% | +$12.8M | 0.24% | 95 |
|
|
2020
Q1 | $10.5M | Buy |
+684,778
| New | +$14.9M | 0.11% | 203 |
|
|
2016
Q3 | – | Sell |
-9,820
| Closed | -$381K | – | 1166 |
|
|
2016
Q2 | $381K | Buy |
+9,820
| New | +$353K | ﹤0.01% | 871 |
|
|
2016
Q1 | – | Sell |
-23,148
| Closed | -$1.25M | – | 1213 |
|
|
2015
Q4 | $1.25M | Buy |
23,148
+4,410
| +24% | +$222K | 0.01% | 664 |
|
|
2015
Q3 | $750K | Buy |
+18,738
| New | +$611K | 0.01% | 671 |
|
Other funds holding ITCI
Marshall Wace's ITCI Position: Q2 2025 in Review
Marshall Wace sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 440,668 shares — an estimated $58.1M sold.
Marshall Wace first reported a position in ITCI in Q3 2015 and held it in 19 quarters. The position peaked at $154M in Q1 2022. 3 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.
- Marshall Wace reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
- Marshall Wace sold 440,668 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $58.1M.
- Marshall Wace first reported a position in Intra-Cellular Therapies Inc. in Q3 2015 and held it in 19 quarters.
- Marshall Wace's Intra-Cellular Therapies Inc. position peaked at $154M in Q1 2022.
- 3 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.
Based on Marshall Wace's 13F filing for Q2 2025, filed 13 Aug 2025.